Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of cxcr4 antagonists

An antagonist, methylene technology, applied in the field of use of CXCR4 antagonists

Inactive Publication Date: 2014-02-19
GENZYME CORP +1
View PDF52 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] None of the aforementioned documents specifically mentions the use of the CXCR4 antagonists disclosed therein for the treatment or prevention of WHIM syndrome or congenital myeloid agranulocytosis or the diseases or conditions disclosed herein

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cxcr4 antagonists
  • Use of cxcr4 antagonists
  • Use of cxcr4 antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0389] Example 1: Clinical Trial Results - Plerixafor is a potential therapy for congenital myeloid agranulocytosis, WHIM syndrome.

[0390] Research design: This is an open-label, single-center, phase I study to examine the hematological effects, pharmacokinetics, and safety of plerixafor in patients with congenital myelogranulocytosis due to CXCR4 mutations. The study used serial, escalating doses of plerixafor administered on days 1, 3, 5, 8, and 10. Five escalating dose levels, 20mcg / kg, 40mcg / kg, 80mcg / kg and 240mcg / kg, were examined daily in patients. Subjects were patients at the University of Washington Comprehensive Clinical Research Center for up to 10 days; the study required subject participation for up to 14 days. Patients were monitored for the hematological effects of plerixafor and observed for adverse reactions. Plerixafor will be discontinued if a normal blood neutrophil count is achieved and maintained for at least 24 hours prior to the highest dose.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist.

Description

[0001] related application [0002] This application claims the benefit of US Provisional Application No. 61 / 486,632, filed May 16, 2011. The entire teachings of the aforementioned applications are incorporated herein by reference. [0003] The disclosed invention is directed to the use of certain CXCR4 antagonists for the treatment or prevention of WHIM syndrome and certain other diseases or conditions, and the use of corresponding pharmaceutical compositions comprising these CXCR4 antagonists. Background of the invention [0004] WHIM (warts, hypogammaglobulinemia, immunodeficiency, congenital myelogranulocytosis) syndrome is a rare disorder characterized by warts, hypogammaglobulinemia, recurrent bacterial infections, and leukocytes Decrease and neutropenia. Neutropenia is thought to be due to congenital myelogranulocytosis, a form of neutropenia associated with abnormal retention of mature neutrophils in the bone marrow and hypercellularity of the bone marrow. Balabania...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D255/02
CPCA61K31/395A61K38/193A61K45/06A61K31/4178A61K31/4427A61K31/52A61K2300/00A61P7/06A61K9/0019A61K2121/00C07D255/02
Inventor D.C.戴尔G.J.布里杰F.J.许
Owner GENZYME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com